PF-Atlas › Clinical Trials › NCT01707290

Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation

Ivacaftor · Phase 3

Registry ID
NCT01707290
Phase
Phase 3
Status
Completed
Drug / intervention
Ivacaftor
Sponsor
Vertex Pharmaceuticals Incorporated
Start
2013-02

About this trial

Ivacaftor is evaluated in NCT01707290, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Completed.

View NCT01707290 on ClinicalTrials.gov →

Explore related

All Ivacaftor trialsAll IPF trials

Related trials

ivacaftor — NCT02445053Ivacaftor — NCT00953706Ivacaftor — NCT01614457Ivacaftor — NCT01705145Ivacaftor — NCT02934698Ivacaftor — NCT03068312
Medical disclaimer. This page summarizes public trial data for NCT01707290 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.